-
Je něco špatně v tomto záznamu ?
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review
T. Van den Broeck, RCN. van den Bergh, N. Arfi, T. Gross, L. Moris, E. Briers, M. Cumberbatch, M. De Santis, D. Tilki, S. Fanti, N. Fossati, S. Gillessen, JP. Grummet, AM. Henry, M. Lardas, M. Liew, O. Rouvière, J. Pecanka, MD. Mason, IG....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy, systematický přehled
- MeSH
- kalikreiny krev MeSH
- lidé MeSH
- lokální recidiva nádoru krev mortalita MeSH
- míra přežití MeSH
- nádory prostaty krev mortalita MeSH
- prognóza MeSH
- prostatický specifický antigen krev MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- systematický přehled MeSH
CONTEXT: In men with prostate cancer (PCa) treated with curative intent, controversy exists regarding the impact of biochemical recurrence (BCR) on oncological outcomes. OBJECTIVE: To perform a systematic review of the existing literature on BCR after treatment with curative intent for nonmetastatic PCa. Objective 1 is to investigate whether oncological outcomes differ between patients with or without BCR. Objective 2 is to study which clinical factors and tumor features in patients with BCR have an independent prognostic impact on oncological outcomes. EVIDENCE ACQUISITION: Medline, Medline In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched. For objective 1, prospective and retrospective studies comparing survival outcomes of patients with or without BCR following radical prostatectomy (RP) or radical radiotherapy (RT) were included. For objective 2, all studies with at least 100 participants and reporting on prognostic patient and tumor characteristics in patients with BCR were included. Risk-of-bias and confounding assessments were performed according to the Quality in Prognosis Studies tool. Both a narrative synthesis and a meta-analysis were undertaken. EVIDENCE SYNTHESIS: Overall, 77 studies were included for analysis, of which 14 addressed objective 1, recruiting 20 406 patients. Objective 2 was addressed by 71 studies with 29 057, 11 301, and 4272 patients undergoing RP, RT, and a mixed population (mix of patients undergoing RP or RT as primary treatment), respectively. There was a low risk of bias for study participation, confounders, and statistical analysis. For most studies, attrition bias, and prognostic and outcome measurements were not clearly reported. BCR was associated with worse survival rates, mainly in patients with short prostate-specific antigen doubling time (PSA-DT) and a high final Gleason score after RP, or a short interval to biochemical failure (IBF) after RT and a high biopsy Gleason score. CONCLUSIONS: BCR has an impact on survival, but this effect appears to be limited to a subgroup of patients with specific clinical risk factors. Short PSA-DT and a high final Gleason score after RP, and a short IBF after RT and a high biopsy Gleason score are the main factors that have a negative impact on survival. These factors may form the basis of new BCR risk stratification (European Association of Urology BCR Risk Groups), which needs to be validated formally. PATIENT SUMMARY: This review looks at the risk of death in men who shows rising prostate-specific antigen (PSA) in the blood test performed after curative surgery or radiotherapy. For many men, rising PSA does not mean that they are at a high risk of death from prostate cancer in the longer term. Men with PSA that rises shortly after they were treated with radiotherapy or rapidly rising PSA after surgery and a high tumor grade for both treatment modalities are at the highest risk of death. These factors may form the basis of new risk stratification (European Association of Urology biochemical recurrence Risk Groups), which needs to be validated formally.
Academic Urology Unit University of Aberdeen Aberdeen UK
Academic Urology Unit University of Sheffield Sheffield UK
Charite Universitätsmedizin Berlin Germany
Department of Biomedical Data Sciences University Medical Center Leiden The Netherlands
Department of Medicine McMaster University Hamilton ON Canada
Department of Oncology and Haematology Cantonal Hospital St Gallen St Gallen Switzerland
Department of Pathology Erasmus Medical Centre Rotterdam The Netherlands
Department of Radiation Oncology University Hospital Ulm Ulm Germany
Department of Surgery Central Clinical School Monash University Caulfield North Victoria Australia
Department of Urology Aberdeen Royal Infirmary Aberdeen UK
Department of Urology Hospital Saint Luc Saint Joseph Lyon France
Department of Urology Leto Hospital Athens Greece
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology Netherlands Cancer Institute Amsterdam The Netherlands
Department of Urology University Hospital Groningen Groningen The Netherlands
Department of Urology University Hospital Hamburg Eppendorf Hamburg Germany
Department of Urology University Hospital St Etienne France
Department of Urology University Hospitals Leuven Leuven Belgium
Department of Urology University of Bern Inselspital Bern Switzerland
Department of Urology Wrightington Wigan and Leigh NHS Foundation Trust Wigan UK
Division of Cancer Sciences University of Manchester and The Christie Manchester UK
Hospices Civils de Lyon Radiology Department Edouard Herriot Hospital Lyon France
Laboratory of Molecular Endocrinology KU Leuven Leuven Belgium
Leeds Cancer Centre St James's University Hospital and University of Leeds Leeds UK
Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany
Nuclear Medicine Division Policlinico S Orsola University of Bologna Italy
Pecanka Consulting Services Prague Czech Republic
Royal Liverpool and Broadgreen Hospitals NHS Trust Liverpool UK
Unit of Urology Division of Oncology URI IRCCS Ospedale San Raffaele Milan Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025834
- 003
- CZ-PrNML
- 005
- 20201222160412.0
- 007
- ta
- 008
- 201125s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2018.10.011 $2 doi
- 035 __
- $a (PubMed)30342843
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Van den Broeck, Thomas $u Department of Urology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium. Electronic address: vandenbroeck.thomas@gmail.com.
- 245 10
- $a Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review / $c T. Van den Broeck, RCN. van den Bergh, N. Arfi, T. Gross, L. Moris, E. Briers, M. Cumberbatch, M. De Santis, D. Tilki, S. Fanti, N. Fossati, S. Gillessen, JP. Grummet, AM. Henry, M. Lardas, M. Liew, O. Rouvière, J. Pecanka, MD. Mason, IG. Schoots, TH. van Der Kwast, HG. van Der Poel, T. Wiegel, PM. Willemse, Y. Yuan, TB. Lam, P. Cornford, N. Mottet,
- 520 9_
- $a CONTEXT: In men with prostate cancer (PCa) treated with curative intent, controversy exists regarding the impact of biochemical recurrence (BCR) on oncological outcomes. OBJECTIVE: To perform a systematic review of the existing literature on BCR after treatment with curative intent for nonmetastatic PCa. Objective 1 is to investigate whether oncological outcomes differ between patients with or without BCR. Objective 2 is to study which clinical factors and tumor features in patients with BCR have an independent prognostic impact on oncological outcomes. EVIDENCE ACQUISITION: Medline, Medline In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched. For objective 1, prospective and retrospective studies comparing survival outcomes of patients with or without BCR following radical prostatectomy (RP) or radical radiotherapy (RT) were included. For objective 2, all studies with at least 100 participants and reporting on prognostic patient and tumor characteristics in patients with BCR were included. Risk-of-bias and confounding assessments were performed according to the Quality in Prognosis Studies tool. Both a narrative synthesis and a meta-analysis were undertaken. EVIDENCE SYNTHESIS: Overall, 77 studies were included for analysis, of which 14 addressed objective 1, recruiting 20 406 patients. Objective 2 was addressed by 71 studies with 29 057, 11 301, and 4272 patients undergoing RP, RT, and a mixed population (mix of patients undergoing RP or RT as primary treatment), respectively. There was a low risk of bias for study participation, confounders, and statistical analysis. For most studies, attrition bias, and prognostic and outcome measurements were not clearly reported. BCR was associated with worse survival rates, mainly in patients with short prostate-specific antigen doubling time (PSA-DT) and a high final Gleason score after RP, or a short interval to biochemical failure (IBF) after RT and a high biopsy Gleason score. CONCLUSIONS: BCR has an impact on survival, but this effect appears to be limited to a subgroup of patients with specific clinical risk factors. Short PSA-DT and a high final Gleason score after RP, and a short IBF after RT and a high biopsy Gleason score are the main factors that have a negative impact on survival. These factors may form the basis of new BCR risk stratification (European Association of Urology BCR Risk Groups), which needs to be validated formally. PATIENT SUMMARY: This review looks at the risk of death in men who shows rising prostate-specific antigen (PSA) in the blood test performed after curative surgery or radiotherapy. For many men, rising PSA does not mean that they are at a high risk of death from prostate cancer in the longer term. Men with PSA that rises shortly after they were treated with radiotherapy or rapidly rising PSA after surgery and a high tumor grade for both treatment modalities are at the highest risk of death. These factors may form the basis of new risk stratification (European Association of Urology biochemical recurrence Risk Groups), which needs to be validated formally.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kalikreiny $x krev $7 D007610
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lokální recidiva nádoru $x krev $x mortalita $7 D009364
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prostatický specifický antigen $x krev $7 D017430
- 650 _2
- $a nádory prostaty $x krev $x mortalita $7 D011471
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a van den Bergh, Roderick C N $u Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- 700 1_
- $a Arfi, Nicolas $u Department of Urology, Hospital Saint Luc Saint Joseph, Lyon, France.
- 700 1_
- $a Gross, Tobias $u Department of Urology, University of Bern, Inselspital, Bern, Switzerland.
- 700 1_
- $a Moris, Lisa $u Department of Urology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Briers, Erik $u Hasselt, Belgium.
- 700 1_
- $a Cumberbatch, Marcus $u Academic Urology Unit, University of Sheffield, Sheffield, UK.
- 700 1_
- $a De Santis, Maria $u Charite Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- 700 1_
- $a Fanti, Stefano $u Nuclear Medicine Division, Policlinico S. Orsola, University of Bologna, Italy.
- 700 1_
- $a Fossati, Nicola $u Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.
- 700 1_
- $a Gillessen, Silke $u Division of Cancer Sciences, University of Manchester and The Christie, Manchester, UK; Department of Oncology and Haematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; University of Bern, Bern, Switzerland.
- 700 1_
- $a Grummet, Jeremy P $u Department of Surgery, Central Clinical School, Monash University, Caulfield North, Victoria, Australia.
- 700 1_
- $a Henry, Ann M $u Leeds Cancer Centre, St. James's University Hospital and University of Leeds, Leeds, UK.
- 700 1_
- $a Lardas, Michael $u Department of Urology, Leto Hospital, Athens, Greece.
- 700 1_
- $a Liew, Matthew $u Department of Urology, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, UK.
- 700 1_
- $a Rouvière, Olivier $u Hospices Civils de Lyon, Radiology Department, Edouard Herriot Hospital, Lyon, France.
- 700 1_
- $a Pecanka, Jakub $u Pecanka Consulting Services, Prague, Czech Republic; Department of Biomedical Data Sciences, University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Mason, Malcolm D $u Division of Cancer & Genetics, School of Medicine Cardiff University, Velindre Cancer Centre, Cardiff, UK.
- 700 1_
- $a Schoots, Ivo G $u Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
- 700 1_
- $a van Der Kwast, Theo H $u Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands.
- 700 1_
- $a van Der Poel, Henk G $u Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- 700 1_
- $a Wiegel, Thomas $u Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany.
- 700 1_
- $a Willemse, Peter-Paul M $u Department of Urology, University Hospital Groningen, Groningen, The Netherlands.
- 700 1_
- $a Yuan, Yuhong $u Department of Medicine, McMaster University, Hamilton, ON, Canada.
- 700 1_
- $a Lam, Thomas B $u Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.
- 700 1_
- $a Cornford, Philip $u Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK.
- 700 1_
- $a Mottet, Nicolas $u Department of Urology, University Hospital, St. Etienne, France.
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 75, č. 6 (2019), s. 967-987
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30342843 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222160408 $b ABA008
- 999 __
- $a ok $b bmc $g 1599979 $s 1116520
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 75 $c 6 $d 967-987 $e 20181017 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20201125
